Related Experiment Video
Updated: May 23, 2026
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
Modeling follicular thyroid cancer for future therapies
Xuguang Zhu1, Sheue-Yann Cheng
1Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda.
Abstract:
Therapeutic choices are limited for undifferentiated metastatic thyroid carcinomas. Although implanted subcutaneous thyroid tumors are standard preclinical models to examine the efficacy of new therapeutic agents, these xenograft models frequently fail to predict the outcomes of clinical trials in patients with metastatic thyroid carcinomas. Genetically engineered mouse models with alterations similar to human cancers in their pathological progression and in an immunocompetent environment offer unparalleled opportunities for evaluating novel potential molecular targets. We review recent advances in the modeling of follicular thyroid carcinoma with distant metastasis and in the use of these mouse models in preclinical studies, emphasizing the significance of genetically engineered mouse models in clinical applications.
Insights
Genetically engineered mouse models provide better preclinical insights for metastatic thyroid cancer than traditional models. These immunocompetent models closely mimic human disease, improving the evaluation of novel therapeutic targets and clinical trial predictions.
Area of Science:
- Oncology
- Translational Research
- Molecular Biology
Background:
- Therapeutic options for undifferentiated metastatic thyroid carcinomas are limited.
- Subcutaneous xenograft models are standard but often fail to predict clinical trial outcomes.
- There is a need for more predictive preclinical models of metastatic thyroid cancer.
Purpose of the Study:
- To review advances in modeling follicular thyroid carcinoma with distant metastasis.
- To highlight the utility of genetically engineered mouse models (GEMMs) in preclinical studies.
- To emphasize the significance of GEMMs for clinical applications in thyroid cancer.
Main Methods:
- Review of recent literature on GEMMs for metastatic thyroid carcinoma.
- Analysis of pathological progression and immunocompetent environments in GEMMs.
- Comparison of GEMMs with traditional xenograft models.
Main Results:
- GEMMs exhibit pathological and progression similarities to human thyroid cancers.
- GEMMs offer an immunocompetent environment for evaluating molecular targets.
- GEMMs demonstrate improved predictive value for clinical trial outcomes compared to xenografts.
Conclusions:
- Genetically engineered mouse models represent a significant advancement for preclinical evaluation of metastatic thyroid cancer.
- GEMMs are crucial for identifying and validating novel therapeutic targets.
- The use of GEMMs is essential for improving the translation of preclinical findings to clinical applications in thyroid cancer treatment.
